VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Viridian Therapeutics, Inc.\DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$20.80+1.77 (+9.30%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Viridian Therapeutics, Inc.\DE income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	71	0.30	0.31	1.77	2.96	1.05	4.46	8.39	4.00	3.48	2.54	6.48	5.49
Cost of Revenue	–	–	–	–	–	–	–	–	–	2.55	2.47	3.37	2.78
Gross Profit	–	–	–	–	–	–	–	–	–	0.93	0.07	3.12	2.71
Research & Development	339	238	160	101	57	28	35	30	20	14	1.00	0.35	0.23
Selling, General & Admin	95	61	95	–	–	–	–	–	–	8.44	10	7.57	1.76
Selling & Marketing	–	–	–	–	–	–	–	–	–	1.67	2.56	0.72	0.35
General & Administrative	–	61	95	35	26	13	12	11	11	6.77	7.69	6.86	1.41
Operating Expenses	434	299	255	136	83	111	46	41	31	20	14	11	4.51
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	16	14	–	–
Operating Income	-363	-299	-254	-134	-80	-110	-42	-33	-27	-17	-11	-6.87	-0.20
Interest Expense	4.95	2.20	1.33	0.49	–	–	–	–	–	0.10	0.14	1.02	1.96
Interest & Investment Income	27	32	18	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	21	29	17	4.43	0.32	0.17	0.94	1.25	0.40	0.04	–	–	–
Merger & Restructuring Charges	–	–	–	–	–	0.30	2.00	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	0	0
Gain (Loss) on Sale of Assets	–	-0.45	0.00	0	-0.08	0	–	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	0.10	0.25
Income Tax Expense	0	–	–	–	–	–	–	–	–	–	0	0	–
Net Income	-343	-270	-238	-130	-79	-111	-42	-33	-27	-17	-11	-7.89	-2.16
Net Income to Common	–	–	–	–	-79	-111	-42	-33	-27	-17	–	-7.89	-2.45
EPS (Basic)(per share)	–	–	-5.31	-4.05	-6.66	-31.13	-20.04	-16.50	-20.70	-423.15	-315.30	-787.50	-2,751.75
EPS (Diluted)(per share)	–	–	-5.31	-4.05	-6.66	-31.13	-20.04	-16.50	-20.70	-423.15	-315.30	-787.50	-2,751.75
Shares Outstanding (Basic, Weighted)(shares)	–	–	45	32	12	3.56	2.09	1.97	1.28	0.04	0.04	0.01	0.00
Shares Outstanding (Diluted, Weighted)(shares)	–	–	45	32	12	3.56	2.09	1.97	1.28	0.04	0.04	0.01	0.00
EBITDA	-363	-298	-254	-134	-80	-110	-42	-33	-26	-17	-11	-6.72	-0.05

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -569.7%
Net margin: -544.1%
Return on equity, FY2025: -49.2%

Financial strength

Current ratio: 16.95
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 258.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –